PNT - Lantheus Downgraded Due To Reliance On PNT2002; Analyst Cites Comparable Profile To Novartis' Drug | Benzinga
Monday, Lantheus Holdings Inc (NASDAQ: LNTH) and POINT Biopharma Global Inc (NASDAQ: PNT) reported topline data from pivotal Phase 3 SPLASH trial of 177Lu-PNT2002 in metastatic castration-resistant prostate cancer after progression on an androgen receptor pathway inhibitor (ARPI).
William Bliar writes that sharing the same survival trend as Novartis AG's (NYSE: NVS) Pluvicto effectively removes a potential bull thesis in which PNT2002 could potentially be on the market before Pluvicto in the disease setting.
The analyst also notes that since Pluvicto demonstrated a numerically lower frequency of high-grade adverse events versus alternate novel hormone therapy in PSMAfore, the safety profile ...